Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Symbol
- BHC
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.13B
- 52 week range
- 4.33 - 8
Valuation
- Share price
- $5.71 (close of 2026-09-23)
- P/E (TTM)
- -1.94x
- Price to book
- -2.66x
- Price to free cash flow
- 1.49x
- Enterprise value
- $21.09B
- Book value per share
- $-2.14
Price performance
| Period | Change |
|---|
| 1 day | +1.24% |
| 5 days | +0.71% |
| 1 month | -11.34% |
| 3 months | +18.96% |
| 6 months | +11.96% |
| Year to date | -17.84% |
| 1 year | -14.90% |
| 3 years | -30.54% |
| 5 years | -80.62% |
| 10 years | -79.40% |
| All time | +1042.00% |
Profitability and growth
- Return on equity
- 41.64%
- Return on invested capital
- 7.86%
- Return on assets
- 0.60%
- Return on capital employed
- 8.17%
- Gross margin
- 51.15%
- Net margin
- 1.53%
- EBITDA margin
- 29.43%
- Revenue growth
- 6.66%
- Net income growth
- 441.30%
- Free cash flow growth
- -20.40%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 67.03%
- Current ratio
- 1.44x
- Net debt to EBITDA
- 9.26x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $10.27B
- Cost of revenue
- $5.01B
- Gross profit
- $5.25B
- EBITDA
- $3.02B
- Net income
- $157.00M
- Earnings per share
- $0.42
- Shares outstanding
- 370.90M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $10.27B | $5.25B | $157.00M | $0.42 |
| 2024-12-31 | $9.63B | $4.84B | $-46.00M | $-0.13 |
| 2023-12-31 | $8.76B | $3.88B | $-592.00M | $-1.62 |
| 2022-12-31 | $8.12B | $3.08B | $-225.00M | $-0.62 |
| 2021-12-31 | $8.43B | $3.07B | $-948.00M | $-2.64 |
| 2020-12-31 | $8.03B | $3.04B | $-560.00M | $-1.58 |
| 2019-12-31 | $8.60B | $2.35B | $-1.79B | $-5.08 |
| 2018-12-31 | $8.38B | $89.00M | $-4.14B | $-11.81 |
| 2017-12-31 | $8.72B | $6.22B | $2.40B | $6.86 |
| 2016-12-31 | $9.67B | $7.10B | $-2.41B | $-6.94 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 51.15% | 1.53% | 41.64% | 7.86% |
| 2024-12-31 | 50.31% | -0.48% | 14.29% | 6.50% |
| 2023-12-31 | 44.31% | -6.76% | 721.95% | 3.47% |
| 2022-12-31 | 37.90% | -2.77% | -86.54% | 1.81% |
| 2021-12-31 | 36.45% | -11.24% | 2788.24% | 2.02% |
| 2020-12-31 | 37.91% | -6.98% | -92.56% | 2.79% |
| 2019-12-31 | 27.33% | -20.79% | -157.39% | -0.62% |
| 2018-12-31 | 1.06% | -49.45% | -147.21% | -8.89% |
| 2017-12-31 | 71.27% | 27.56% | 40.44% | 0.33% |
| 2016-12-31 | 73.41% | -24.89% | -73.91% | -1.66% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $1.31B | $20.59B |
| 2024-12-31 | $1.18B | $18.94B |
| 2023-12-31 | $947.00M | $21.94B |
| 2022-12-31 | $564.00M | $20.33B |
| 2021-12-31 | $582.00M | $22.65B |
| 2020-12-31 | $605.00M | $23.93B |
| 2019-12-31 | $3.24B | $24.66B |
| 2018-12-31 | $721.00M | $24.08B |
| 2017-12-31 | $720.00M | $25.23B |
| 2016-12-31 | $542.00M | $29.84B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $1.00B | $216.00M |
| 2024-12-31 | $1.26B | $150.00M |
| 2023-12-31 | $817.00M | $132.00M |
| 2022-12-31 | $-946.00M | $126.00M |
| 2021-12-31 | $1.16B | $128.00M |
| 2020-12-31 | $809.00M | $105.00M |
| 2019-12-31 | $1.23B | $102.00M |
| 2018-12-31 | $1.34B | $87.00M |
| 2017-12-31 | $2.12B | $87.00M |
| 2016-12-31 | $1.85B | $165.00M |
Dividend history
- Most recent payment
- 2010-11-10
| Payment date | Dividend per share |
|---|
| 2010-11-10 | $1.00 |
| 2010-08-30 | $0.10 |
| 2010-05-28 | $0.10 |
| 2010-03-04 | $0.09 |
| 2009-11-30 | $0.09 |
| 2009-08-28 | $0.09 |
| 2009-05-13 | $0.09 |
| 2009-03-06 | $0.38 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $1.08
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $0.96 |
| 2026-04-29 | - | - |
| 2026-02-18 | - | - |
| 2025-10-29 | - | - |
| 2025-07-30 | - | - |
| 2025-04-30 | - | - |
| 2025-02-20 | - | - |
| 2025-02-19 | - | - |
Filings and sources
- Company website
- bauschhealth.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades